Table. 3.
Incidence of adverse events
| Characteristic | Bevacizumab, n (%) (N = 82) | Lenvatinib, n (%) (N = 152) | p value1 | |||
|---|---|---|---|---|---|---|
| Any grade | Grades 3 and 4 | Any grade | Grades 3 and 4 | Any grade | Grades 3 and 4 | |
| Overall incidence | 75 (91) | 31 (38) | 130 (86) | 52 (34) | 0.22 | 0.67 |
| Elevated GGT | 35 (43) | 8 (9.8) | 79 (52) | 14 (9.2) | 0.40 | 1.00 |
| Elevated AST | 45 (55) | 6 (7.3) | 79 (52) | 10 (6.6) | 0.68 | 0.79 |
| Decreased HGB | 36 (44) | 4 (4.9) | 69 (45) | 10 (6.6) | 0.89 | 0.78 |
| Elevated ALP | 27 (33) | 2 (2.4) | 55 (36) | 4 (2.6) | 0.67 | 1.00 |
| Decreased PLT | 32 (39) | 10 (12) | 45 (30) | 9 (5.9) | 0.15 | 0.13 |
| Elevated ALT | 24 (29) | 7 (8.5) | 41 (27) | 5 (3.3) | 0.76 | 0.12 |
| Decreased WBC | 13 (16) | 1 (1.2) | 26 (17) | 2 (1.3) | 0.86 | 1.00 |
| Proteinuria | 8 (9.8) | 3 (3.7) | 24 (16) | 9 (5.9) | 0.24 | 0.55 |
| GI bleeding | 19 (23) | 12 (15) | 21 (14) | 12 (7.9) | 0.10 | 0.12 |
GGT, gamma-glutamyl transferase.
1Fisher’s exact test.